PLX
Protalix Biotherapeutics Inc
2.80$
-1.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -66.6% | 34.3% | 111.7% | -26.8% | 22.9% | 21.9% | -50.0% | -33.4% | -20.9% | 22.3% | 65.3% | -52.3% | 12.3% | |
| 2.9% | 3.5% | 8.6% | 2.4% | 1.8% | 1.8% | 3.4% | 2.3% | 2.1% | 4.2% | 1.2% | 2.0% | 1.9% | |
| 10.6% | 13.0% | 26.2% | 7.4% | 3.5% | 3.6% | 5.3% | 2.7% | 3.3% | 8.0% | 1.6% | 2.0% | 2.8% | |
| -58.7% | 60.1% | 215.7% | -16.0% | -9.3% | -18.9% | -18.2% | -44.1% | -40.0% | 63.3% | 7.5% | -78.2% | -17.8% | |
| 4.3% | 2.4% | 16.0% | 1.3% | 0.5% | 2.3% | 3.0% | 2.8% | 2.8% | 4.4% | 2.3% | 3.0% | 2.8% | |
| -201.8% | -3.3% | -16.2% | -1.3% | 113.2% | -84.1% | -3.1% | -2.8% | -2.8% | -12.2% | 12.5% | -18.3% | -1.3% | |
| 238.4% | – | – | – | 0.0% | 19.9% | 50.2% | 58.6% | 51.4% | 102.2% | – | – | – | |
| – | – | – | – | – | 0.0% | – | – | – | – | – | – | – | |
| 238.4% | 0.0% | 0.0% | 0.0% | -113.7% | 19.9% | 50.2% | 26.2% | 51.4% | 1.6% | 0.4% | 0.0% | 11.8% | |
| -268.5% | 30.8% | 95.4% | -28.3% | 22.3% | -42.0% | -3.0% | -10.0% | -23.8% | 11.3% | 78.0% | -68.3% | 11.8% | |
| -70.9% | 31.9% | 95.8% | -28.1% | 22.4% | 19.6% | -53.0% | -36.2% | -23.7% | 17.8% | 63.0% | -55.3% | 9.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.